SION
Sionna Therapeutics·NASDAQ
--
--(--)
--
--(--)
SION fundamentals
During Q4 2025, Sionna Therapeutics (SION) reported revenue of --, a YoY change of 0.00%. Net income was -20.44M, a YoY change of -28.98%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 12.60M -- | 13.15M -- | 11.29M -- | 27.98M -- | 18.13M +43.97% | 19.66M +49.53% | 21.91M +94.00% | 23.80M -14.93% | 23.61M +30.22% | 88.98M -- |
Selling, General and Administrative Expenses | 2.71M -- | 2.93M -- | 3.06M -- | 3.40M -- | 3.88M +43.44% | 5.99M +104.68% | 6.52M +113.24% | 7.76M +128.13% | 8.44M +117.63% | 28.72M -- |
General and Administrative Expenses | 2.71M -- | 2.93M -- | 3.06M -- | 3.40M -- | 3.88M +43.44% | 5.99M +104.68% | 6.52M +113.24% | 7.76M +128.13% | 8.44M +117.63% | 28.72M -- |
Research and Development Expenses | 9.89M -- | 10.22M -- | 8.23M -- | 24.58M -- | 14.25M +44.12% | 13.67M +33.74% | 15.38M +86.85% | 16.04M -34.73% | 15.17M +6.42% | 60.26M -- |
Operating Income | -12.60M -- | -13.15M -- | -11.29M -- | -27.98M -- | -18.13M -43.97% | -19.66M -49.53% | -21.91M -94.00% | -23.80M +14.93% | -23.61M -30.22% | -88.98M -- |
Non-Operating Income (Loss) | 719.00K -- | 1.30M -- | 2.74M -- | 2.54M -- | 2.29M +217.80% | 3.18M +144.38% | 3.84M +40.07% | 3.53M +38.69% | 3.17M +38.82% | 13.71M -- |
Other Non-Operating Income (Loss) | 166.00K -- | 168.00K -- | 174.00K -- | 190.00K -- | 166.00K -- | 177.00K +5.36% | 171.00K -1.72% | 71.00K -62.63% | 0 -100.00% | 419.00K -- |
Net Interest Expense | -553.00K -- | -1.13M -- | -2.57M -- | -2.35M -- | -2.12M -283.18% | -3.00M -165.02% | -3.67M -42.91% | -3.46M -46.88% | -3.17M -49.69% | -13.29M -- |
Interest Income | 553.00K -- | 1.13M -- | 2.57M -- | 2.35M -- | 2.12M +283.18% | 3.00M +165.02% | 3.67M +42.91% | 3.46M +46.88% | 3.17M +49.69% | 13.29M -- |
Pretax Income From Continuing Operations | -11.88M -- | -11.85M -- | -8.55M -- | -25.44M -- | -15.85M -33.45% | -16.48M -39.12% | -18.07M -111.27% | -20.28M +20.29% | -20.44M -28.98% | -75.27M -- |
Net Income | -11.88M -- | -11.85M -- | -8.55M -- | -25.44M -- | -15.85M -33.45% | -16.48M -39.12% | -18.07M -111.27% | -20.28M +20.29% | -20.44M -28.98% | -75.27M -- |
Net Income Attributable to Owners of the Company | -11.88M -- | -11.85M -- | -8.55M -- | -25.44M -- | -15.85M -33.45% | -16.48M -39.12% | -18.07M -111.27% | -20.28M +20.29% | -20.44M -28.98% | -75.27M -- |
Net Income Attributable to Common Stockholders | -11.88M -- | -11.85M -- | -8.55M -- | -25.44M -- | -15.85M -33.45% | -16.48M -39.12% | -18.07M -111.27% | -20.28M +20.29% | -20.44M -28.98% | -75.27M -- |
Other Comprehensive Income | -2.00K -- | -8.00K -- | -148.00K -- | 929.00K -- | -405.00K -20150.00% | -67.00K -737.50% | -118.00K +20.27% | 237.00K -74.49% | 120.00K +129.63% | 172.00K -- |
Total Comprehensive Income | -11.88M -- | -11.86M -- | -8.70M -- | -24.51M -- | -16.25M -36.83% | -16.55M -39.60% | -18.19M -109.03% | -20.04M +18.24% | -20.32M -25.02% | -75.10M -- |
Total Comprehensive Income Attributable to Owners of the Company | -11.88M -- | -11.86M -- | -8.70M -- | -24.51M -- | -16.25M -36.83% | -16.55M -39.60% | -18.19M -109.03% | -20.04M +18.24% | -20.32M -25.02% | -75.10M -- |
Basic EPS | -- -- | -3.84 -- | -2.71 -- | -5.67 -- | -- -- | -0.62 +83.85% | -0.41 +84.87% | -0.46 +91.89% | -0.46 -- | -1.95 -- |
Basic EPS from Continuing Operations | -- -- | -3.84 -- | -2.71 -- | -5.67 -- | -- -- | -0.62 +83.85% | -0.41 +84.87% | -0.46 +91.89% | -- -- | -- -- |
Diluted EPS | -- -- | -3.84 -- | -2.71 -- | -5.67 -- | -- -- | -0.62 +83.85% | -0.41 +84.87% | -0.46 +91.89% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -3.84 -- | -2.71 -- | -5.67 -- | -- -- | -0.62 +83.85% | -0.41 +84.87% | -0.46 +91.89% | -- -- | -- -- |
You can ask Aime
What factors drove the changes in Sionna Therapeutics's revenue and profit?Did Sionna Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Sionna Therapeutics's earnings call?What guidance did Sionna Therapeutics's management provide for the next earnings period?What were the key takeaways from Sionna Therapeutics’s earnings call?What is Sionna Therapeutics's gross profit margin?What is the revenue and EPS growth rate for Sionna Therapeutics year over year?What is the market's earnings forecast for Sionna Therapeutics next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
